🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
13.29
-0.05 (-0.37%)
Nov 20, 2026, 12:35 PM EST - Market open

ADMA Biologics Statistics

Total Valuation

ADMA Biologics has a market cap or net worth of $2.95 billion. The enterprise value is $3.03 billion.

Market Cap2.95B
Enterprise Value 3.03B

Important Dates

The last earnings date was Wednesday, November 4, 2026, after market close.

Earnings Date Nov 4, 2026
Ex-Dividend Date n/a

Share Statistics

ADMA Biologics has 221.85 million shares outstanding. The number of shares has decreased by -1.28% in one year.

Current Share Class 221.85M
Shares Outstanding 221.85M
Shares Change (YoY) -1.28%
Shares Change (QoQ) -1.96%
Owned by Insiders (%) 1.89%
Owned by Institutions (%) 85.80%
Float 205.22M

Valuation Ratios

The trailing PE ratio is 17.24 and the forward PE ratio is 16.31.

PE Ratio 17.24
Forward PE 16.31
PS Ratio 5.70
Forward PS 5.05
PB Ratio 6.78
P/TBV Ratio 6.81
P/FCF Ratio 22.27
P/OCF Ratio 21.02
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 12.62, with an EV/FCF ratio of 22.86.

EV / Earnings 16.65
EV / Sales 5.85
EV / EBITDA 12.62
EV / EBIT 13.02
EV / FCF 22.86

Financial Position

The company has a current ratio of 6.04, with a Debt / Equity ratio of 0.46.

Current Ratio 6.04
Quick Ratio 3.08
Debt / Equity 0.46
Debt / EBITDA 0.84
Debt / FCF 1.53
Interest Coverage 22.04

Financial Efficiency

Return on equity (ROE) is 41.95% and return on invested capital (ROIC) is 36.54%.

Return on Equity (ROE) 41.95%
Return on Assets (ROA) 22.41%
Return on Invested Capital (ROIC) 36.54%
Return on Capital Employed (ROCE) 36.60%
Weighted Average Cost of Capital (WACC) 7.62%
Revenue Per Employee $802,400
Profits Per Employee $281,937
Employee Count647
Asset Turnover 0.80
Inventory Turnover 0.71

Taxes

In the past 12 months, ADMA Biologics has paid $52.15 million in taxes.

Income Tax 52.15M
Effective Tax Rate 22.23%

Stock Price Statistics

The stock price has decreased by -16.93% in the last 52 weeks. The beta is 0.66, so ADMA Biologics's price volatility has been lower than the market average.

Beta (5Y) 0.66
52-Week Price Change -16.93%
50-Day Moving Average 10.98
200-Day Moving Average 10.64
Relative Strength Index (RSI) 63.32
Average Volume (20 Days) 4,140,211

Short Selling Information

The latest short interest is 18.04 million, so 8.13% of the outstanding shares have been sold short.

Short Interest 18.04M
Short Previous Month 19.53M
Short % of Shares Out 8.13%
Short % of Float 8.79%
Short Ratio (days to cover) 6.47

Income Statement

In the last 12 months, ADMA Biologics had revenue of $519.15 million and earned $182.41 million in profits. Earnings per share was $0.77.

Revenue519.15M
Gross Profit 355.76M
Operating Income 233.25M
Pretax Income 234.56M
Net Income 182.41M
EBITDA 240.70M
EBIT 233.25M
Earnings Per Share (EPS) $0.77
Full Income Statement

Balance Sheet

The company has $124.56 million in cash and $202.80 million in debt, with a net cash position of -$78.25 million or -$0.35 per share.

Cash & Cash Equivalents 124.56M
Total Debt 202.80M
Net Cash -78.25M
Net Cash Per Share -$0.35
Equity (Book Value) 438.51M
Book Value Per Share 1.97
Working Capital 480.59M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $140.80 million and capital expenditures -$7.89 million, giving a free cash flow of $132.91 million.

Operating Cash Flow 140.80M
Capital Expenditures -7.89M
Depreciation & Amortization 7.46M
Net Borrowing 122.66M
Free Cash Flow 132.91M
FCF Per Share $0.60
Full Cash Flow Statement

Margins

Gross margin is 68.53%, with operating and profit margins of 44.93% and 35.14%.

Gross Margin 68.53%
Operating Margin 44.93%
Pretax Margin 45.18%
Profit Margin 35.14%
EBITDA Margin 46.36%
EBIT Margin 44.93%
FCF Margin 25.60%

Dividends & Yields

ADMA Biologics does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield 1.28%
Shareholder Yield 1.28%
Earnings Yield 5.80%
FCF Yield 4.49%

Analyst Forecast

The average price target for ADMA Biologics is $18.00, which is 35.44% higher than the current price. The consensus rating is "Buy".

Price Target $18.00
Price Target Difference 35.44%
Analyst Consensus Buy
Analyst Count 4
Revenue Growth Forecast (3Y) 11.03%
EPS Growth Forecast (3Y) 22.37%
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number
Graham Upside
Graham Formula Value
Graham Formula Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

ADMA Biologics has an Altman Z-Score of 8.61 and a Piotroski F-Score of 4.

Altman Z-Score 8.61
Piotroski F-Score 4